Chemoprevention of Prostate Cancer with the Polyamine Synthesis Inhibitor Difluoromethylornithine

  • Frank L. MeyskensJr.Email author
  • Anne R. Simoneau
  • Eugene W. Gerner
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)


In vitro and in vivo preclinical results suggest that inhibition of polyamine synthesis inhibits the progression of prostate cancer. These findings has led to two clinical trials in patients at risk for invasive prostate cancer with difluoromethylornithine which specifically and irreversibly inhibits ornithine decarboxylase which catalyses the conversion of ornithine to putrescine the rate limiting step in polyamines synthesis. We have conducted a phase IIa one month and placebo randomized phase IIb 12 months trials in patients at increased risk for invasive prostate cancer. Favorable reduction in prostate polyamine levels and prostate volume was documented with no difference in clinical hearing changes. Patients with Gleason’s VI lesions in a surveillance cohort would be appropriate candidates for a definitive risk reduction trial although the unavailability of validated biomarkers for invasive progression would require a large and lengthy study.


Prostate Cancer Prostate Volume Polyamine Level Polyamine Synthesis Prostate Needle Biopsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Agostinelli E, Marques MP, Calheiros R, Gil FP, Tempera G, Viceconte N, Battaglia V, Grancara S, Toninello A (2010) Polyamines: fundamental characters in chemistry and biology. Amino Acids 38(2):393–403. doi: 10.1007/s00726-009-0396-7. Epub 2009 Dec 15. Review. PubMed PMID: 20013011
  2. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP (2013) Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 73(3):328–335. doi:  10.1002/pros.22573. Epub 2012 Aug 10. PubMed PMID:22887343Google Scholar
  3. Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, Russo GI, Morgia G (2012) Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012:632959. doi: 10.1155/2012/632959. Epub 2012 May 28. Review. PubMed PMID: 22690272; PubMed Central PMCID: PMC3368543
  4. Earnshaw SR, Brogan AP, McDade CL (2013) Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics 31(4):289–304. doi: 10.1007/s40273-013-0037-6. PubMed PMID: 23519744Google Scholar
  5. Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G (2013) Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. Jan 17. doi:  10.1002/pros.22644. [Epub ahead of print] PubMed PMID: 23335089
  6. Gerner EW, Meyskens FL Jr. (2004) Polyamines and cancer: old molecules, newunderstanding. Nat Rev Cancer 4(10):781–792. Review. PubMed PMID:15510159Google Scholar
  7. Horie S (2012) Chemoprevention of prostate cancer: soy isoflavones and curcumin. Korean J Urol 53(10):665–672. doi: 10.4111/kju.2012.53.10.665. Epub 2012 Oct 19. PubMed PMID: 23136625; PubMed Central PMCID: PMC3490085Google Scholar
  8. Kadmon D (1992) Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J Cell Biochem Suppl 16H:122–127. Review.PubMed PMID: 1289667Google Scholar
  9. Kreul SM, Havighurst T, Kim K, Mendonça EA, Wood GS, Snow S, Borich A, Verma A, Bailey HH (2012) A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila) 5(12):1368–1374. doi:  10.1158/1940-6207.CAPR-12-0233. Epub 2012 Oct 11. PubMed PMID: 23060038; PubMed Central PMCID: PMC3518692
  10. McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL Jr (2008) Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 1(7):514–521. doi: 10.1158/1940-6207.CAPR-08-0074. PubMed PMID: 19139001; PubMed Central PMCID: PMC2702261
  11. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1(1):32–38. doi:  10.1158/1940-6207.CAPR-08-0042. PubMed PMID: 18841250; PubMed Central PMCID: PMC2562024Google Scholar
  12. Nowotarski SL, Woster PM, Casero RA Jr (2013) Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med 15:e3. doi: 10.1017/erm.2013.3. PubMed PMID: 23432971
  13. Ozten-Kandaş N, Bosland MC (2011) Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence. J Carcinog 10:27. doi:  10.4103/1477-3163.90438. Epub 2011 Nov 30. PubMed PMID: 22190869; PubMed Central PMCID: PMC3243088
  14. Pan DL, Samavedi S, Eldefrawy A, Manoharan M (2012) The current status of active surveillance for prostate cancer. Postgrad Med 124(3):50–58. doi: 10.3810/pgm.2012.05.2548. Review. PubMed PMID: 22691899Google Scholar
  15. Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Sholler G (2013) AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer. Mar 2. doi: 10.1002/ijc.28139. [Epub ahead of print] PubMed PMID: 23457004
  16. Seiler N (2003) Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 4(7):537–564. Review. PubMed PMID: 14535654Google Scholar
  17. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL Jr (2001) Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst 93(1):57–59. PubMed PMID: 11136843Google Scholar
  18. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 17(2):292–299. doi: 10.1158/1055-9965.EPI-07-0658. PubMed PMID: 18268112; PubMed Central PMCID: PMC2515594
  19. Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steiner M (2013) Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 31(5):523–529. doi:  10.1200/JCO.2012.41.7634. Epub 2013 Jan 7. PubMed PMID: 23295793Google Scholar
  20. Thapa D, Ghosh R (2012) Antioxidants for prostate cancer chemoprevention: challenges and opportunities. Biochem Pharmacol 83(10):1319–1330. doi: 10.1016/j.bcp.2011.12.027. Epub 2012 Jan 11. Review. PubMed PMID: 22248733Google Scholar
  21. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224. Epub 2003 Jun 24. PubMed PMID: 12824459Google Scholar
  22. Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL (2010) Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J Natl Cancer Inst 102(19):1513–1516. doi: 10.1093/jnci/djq325. Epub 2010 Aug 26. PubMed PMID: 20798393; PubMed Central PMCID: PMC2950167Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Frank L. MeyskensJr.
    • 1
    • 2
    Email author
  • Anne R. Simoneau
    • 1
    • 3
  • Eugene W. Gerner
    • 4
  1. 1.Chao Family Comprehensive Cancer CenterUniversity of California IrvineIrvineUSA
  2. 2.Departments of Medicine, Biological Chemistry and Public HealthUniversity of California IrvineIrvineUSA
  3. 3.Departmentof UrologyUniversity of California IrvineIrvineUSA
  4. 4.BIO5 Institute and Arizona Cancer CenterUniversity of ArizonaTucsonUSA

Personalised recommendations